0001225208-20-004163.txt : 20200303 0001225208-20-004163.hdr.sgml : 20200303 20200303161502 ACCESSION NUMBER: 0001225208-20-004163 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200228 FILED AS OF DATE: 20200303 DATE AS OF CHANGE: 20200303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nanavaty Maulik CENTRAL INDEX KEY: 0001529708 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 20682401 MAIL ADDRESS: STREET 1: BOSTON SCIENTIFIC CORPORATION STREET 2: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 4 1 doc4.xml X0306 4 2020-02-28 0000885725 BOSTON SCIENTIFIC CORP BSX 0001529708 Nanavaty Maulik 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 1 SVP & Pres, Neuromodulation Common Stock 2020-02-28 4 M 0 1629.0000 0.0000 A 267539.0000 D Common Stock 2020-02-28 4 F 0 808.0000 37.3900 D 266731.0000 D Common Stock 2020-03-02 4 M 0 9623.0000 16.3100 A 276354.0000 D Common Stock 2020-03-02 4 S 0 16763.0000 37.4744 D 259591.0000 D Deferred Stock Units 2020-02-28 4 M 0 1629.0000 0.0000 D 2022-02-28 Common Stock 1629.0000 3259.0000 D Stock Option (Right to Buy) 16.3100 2020-03-02 4 M 0 9623.0000 0.0000 D 2025-02-23 Common Stock 9623.0000 0.0000 D Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $37.35 to $37.655, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 28, 2018, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 23, 2016, the first anniversary of the date of grant. /s/ Scott G. Hodgdon, Attorney-in-Fact 2020-03-03